NCT02453048View on ClinicalTrials.gov

Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

December 31, 2017

Conditions
PertussisWhooping Cough
Interventions
BIOLOGICAL

BPZE1

Intranasal live, attenuated vaccine

OTHER

Placebo

Diluent

Trial Locations (1)

141 86

Karolinska University Hospital, Huddinge

All Listed Sponsors
lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT02453048 - Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine | Biotech Hunter | Biotech Hunter